补肾柔肝方联合重组人干扰素治疗高危型人乳头瘤病毒持续感染42例的临床疗效  

Clinical efficacy of Bushen Rougan decoction combined with recombinant human interferon in the treatment of 42 patients with high-risk human papillomavirus persistent infection

作　　者：毕亚菊 杨洁[1] 梁志超[1] BI Yaju;YANG Jie;LIANG Zhichao(Department of Gynecology,Shijiazhuang Hospital of Traditional Chinese Medicine,Shijiazhuang,Hebei 050000,China)

机构地区：[1]石家庄市中医院妇科,河北石家庄050000

出　　处：《安徽医药》2022年第7期1453-1457,共5页Anhui Medical and Pharmaceutical Journal

基　　金：河北省中医药管理局资助项目(2019446)。

摘　　要：目的 探讨补肾柔肝方联合重组人干扰素治疗高危型人乳头瘤病毒(HPV)持续感染的临床疗效及安全性。方法 选取2017年月至2019年12月石家庄市中医院收治的84例高危型HPV持续感染病人,按随机数字表法分为对照组和试验组各42例。对照组给予重组人干扰素阴道上药,试验组在对照组基础上给予补肾柔肝方颗粒。比较治疗后高危型HPV转阴率、临床疗效、不良反应、血清炎性因子C反应蛋白(CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)及外周血CD4+、CD8+T淋巴细胞的表达及CD4+/CD8+比值的差异性。结果 治疗后试验组总转阴率83.34%(35/42)高于对照组总转阴率61.9%(26/42)(P<0.001);试验组总有效率95.24%(40/42)高于对照组总有效率76.19%(32/40)(P<0.05);试验组总不良反应发生率为4.76%(2/42)低于对照组总不良反应发生率14.28%(6/42)(P>0.05);治疗后两组病人外周血CD8+T细胞百分率低于治疗前,外周血CD4+细胞百分率、CD4+/CD8+比值高于治疗前(P<0.001),且治疗后试验组外周血CD8+T细胞百分率低于对照组,外周血CD4+细胞百分率、CD4+/CD8+比值高于对照组(P<0.001);治疗后两组病人的CRP、IL-6、PCT水平低于治疗前(P<0.001),且治疗后试验组的CRP、IL-6、PCT水平均低于对照组(P<0.001)。结论 补肾柔肝方联合重组人干扰素治疗高危型HPV持续感染的临床疗效显著,不良反应小,安全性高,且可提高机体免疫力,降低血清炎性因子水平。Objective To explore the clinical efficacy and safety of Bushen Rougan decoction combined with recombinant human interferon in the treatment of high-risk HPV persistent infection.MethodA selection of 84 patients with high-risk HPV persistent infection who were admitted to Shijiazhuang Hospital of Traditional Chinese Medicine from January 2017 to December 2019 were selected and assigned into the control group and the test group with 42 cases each according to a random number table.The control group was given recombinant human interferon vaginal medicine,while the test group was given Bushen Rougan Fang granules on the basis of the control group.The high-risk HPV negative rate,clinical efficacy,adverse reactions,serum inflammatory factors C-reactive protein(CRP),interleukin-6(IL-6),and calcitonin after treatment Procalcitonin(PCT) and the expression of CD4+ and CD8+ T lymphocytes in peripheral blood and the difference of CD4+/CD8+ ratio were compared.Results After treatment,the total negative conversion rate of the test group [83.34%(35/42)] was higher than that of the control group [61.9%(26/42)](P<0.001);the total effective rate of the test group [95.24%(40/42)] was higher than that of the control group [76.19%(32/40)](P<0.05);the total adverse reaction rate of the test group [4.76%(2/42)] was lower than that of the control group [14.28%(6/42)]( P>0.05);after treatment,the percentage of CD8+T cells in the peripheral blood of the two groups was lower than that before treatment,the percentage of peripheral blood CD4+ cells and the ratio of CD4+/CD8+ were higher than before treatment(P<0.001),and the percentage of CD8+ T cells in peripheral blood after treatment of the test group was lower than that of the control group,and the percentage of peripheral blood CD4+ cells and the ratio of CD4+/CD8+ were higher than those of the control group(P<0.001);after treatment,the levels of CRP,IL-6 and PCT of the two groups were lower than before treatment(P<0.001),and the levels of CRP,IL-6 and PCT in the test group after treat

关 键 词：乳头状瘤病毒感染 补肾柔肝方 重组人干扰素 C反应蛋白质 CD4淋巴细胞计数 人乳头瘤病毒 临床疗效 

分 类 号：R711.32[医药卫生—妇产科学]